Monday, 6 July 2020

BioLargo completes prototype for PFAS treatment system, ready for pilot testing




BioLargo (OTCQB: BLGO) CEO Dennis Calvert Calvert joined Steve Darling from Proactive with news the company has completed manufacturing on its first prototype unit of their patented BioLargo AEC to tackle PFAS contamination.

Calvert told Proactive the next step and he also told investors about a new product from their Clyra Medical called Clyraguard.

Saturday, 4 July 2020

Clyra Medical Technologies- work with Clyraguard and inactivation of SARS CoV-2 Published




RESEARCH ARTICLE 

In vitro efficacy of a copper iodine complex PPE disinfectant for SARS-CoV-2 inactivation

 [version 1; peer review: awaiting peer review]
Emily Mantlo1Tanya Rhodes2Jenny Boutros3Laura Patterson-Fortin3Alex Evans
 https://orcid.org/0000-0003-4319-1743
4Slobodan Paessler1



Thursday, 2 July 2020

BioLargo Engineering Completes Prototype for PFAS Treatment System and Prepares for First Pilot Projects


Westminster, CA – July 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced that its wholly owned subsidiary BioLargo Engineering, Science & Technologies (BLEST) has completed manufacturing on its first prototype unit of its patented BioLargo AECTM (“Aqueous Electrostatic Concentrator”). This prototype is being tested and will be installed on-site for its first field pilot in the coming months, where the technology will be vetted in tough field conditions for its ability to effectively and affordably eliminate per- and poly-fluoroalkyl substances (“PFAS”) contaminants from water. The technology has already been proven in lab-scale studies to eliminate +99% of PFAS from water in continuous flow while consuming as low as $0.30 in electrical costs per 1,000 gallons treated, representing a significant potential cost savings compared to incumbent PFAS solutions like reverse osmosis and carbon sequestration technologies.

Described as “forever chemicals” by Washington DC based environmental watchdog the Environmental Working Group, PFAS contamination is estimated to affect up to 110 million people in the United States. Numerous experts have linked PFAS to detrimental effects on human health and the environment due to their tendency to accumulate and persist in the environment and human body. On January 7, 2020, EPA Administrator Andrew Wheeler announced that “aggressively addressing per-and polyfluoroalkyl substances (PFAS) is an active and ongoing priority for the U.S. Environmental Protection Agency.” PFAS are found in common household and industrial products, and municipalities are struggling to find a feasible and affordable solution to remove these contaminants from their drinking water.

The BioLargo AEC is intended for two primary markets in the U.S. and abroad: 1) treatment of municipal drinking water to remove PFAS contamination, and 2) treatment and remediation of groundwater contaminated by PFAS. Recent estimates suggest that the total addressable market for PFAS water treatment within the U.S. will grow to $3.1B annually by 2030.

Once the first field pilot projects for the AEC have been successfully completed, the company intends to commence the first commercial trials for the AEC.

Speaking on the future of the BioLargo AEC, BioLargo Engineering President Randall Moore commented, “As with any new technology, the first field pilots are a critical step for the AEC. We are confident our prototype will quickly gain recognition for its unmatched cost-efficiency for removal of PFAS, a technical challenge that has not yet been solved in a broadly feasible and affordable way. The AEC was designed from the ground-up to be a low-OPEX system that consumes very little electricity, and its components are easily sourced, durable, and affordable for most prospective installations.”

BioLargo, Inc. President & CEO Dennis P. Calvert commented, “Experts predict removing PFAS from groundwater and contaminated soil will takes decades to complete. Current PFAS technologies are expensive, inefficient, and cumbersome.  Our engineering team are experts in this area, and this innovative AEC technology would not be possible without their extensive industry experience. We have key relationships in the water industry that can help prove out our AEC performance metrics and leverage the global opportunity through partnerships.”
























About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard) an FDA Registered, hospital grade disinfectant for PPE including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Wednesday, 1 July 2020

BioLargo Subsidiary Odor-No-More Rebrands as ONM Environmental, Inc. to Highlight Expanded Services and Capabilities


Westminster, CA – July 1, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced that its wholly owned subsidiary Odor-No-More, Inc. has changed its name to “ONM Environmental, Inc. as part of a rebranding effort to highlight the expanded services and products offered by the company, and to reflect its growing scope of capabilities. (www.ONMenvironmental.com)

ONM Environmental, Inc. is a turn-key solution provider specializing in cutting-edge products and services to serve multiple industries, offering construction services, municipal solid waste management consulting, environmental engineering, field operations technical support, and its odor and volatile organic compound control products and services. Having been serving leading companies in the waste handling industry, the company has developed an expanded portfolio of technical skills and talent to serve a broad range of industries.

ONM Environmental President Joseph Provenzano commented, “In response to customer demand, we have expanded our product and service offerings over the last few years, become a licensed contractor, and worked closely with BioLargo’s engineering team. With the addition of industry experts, and the significant expansion of our construction and maintenance capabilities, we provide unparalleled product and service solutions to environmental challenges associated with commercial and industrial operations.”

Visit ONM Environmental, Inc. on the web at www.onmenvironmental.com for additional product and service information.


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Monday, 8 June 2020

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com

Click here to listen to the interview!




AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental engineering company, today announced that a new audio interview with the Company is now available.

The interview featuring an overview of BLGO’s current news and moves can be heard at https://www.smallcapvoice.com/interview-biolargo-blgo/.

Dennis P. Calvert, President & CEO of BioLargo, discussed the Company’s business model and market segments with SmallCapVoice.com. With a wide array of issued patents, an extensive R&D talent pool, and a full-service engineering team, the company maintains a robust pipeline of products from inception through maturity.  BioLargo monetizes its technology assets with the goal of maximizing both impact and shareholder value, using licensing, strategic partnership, and direct-to-market strategies.

Recently, the Company’s patented CupriDyne® technology has been proven in a third-party study to be effective in inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. In addition, BioLargo announced in May 2020 that Clyraguard, the product developed by its partially owned subsidiary Clyra Medical Technologies in response to the COVID-19 pandemic, has been successfully shown to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing.

In the interview, Calvert commented, “As the [COVID-19] pandemic took hold, our teams had to ask themselves, ‘how do we make a difference’. At each level, our operating units took a deep dive looking at our portfolio of technologies and assets to come up with our unique responses. This has been the busiest, most intense, but also most unifying time for our team in the history of the Company. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.

About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About SmallCapVoice.com
SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at;




Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

For SmallCapVoice.com:
Stuart T. Smith
512-267-2430
ssmith@smallcapvoice.com
Source: SmallCapVoice.com

Thursday, 4 June 2020

BioLargo Discusses Clyraguard, BioLargo PFAS Treatment Technology Scale-up and Commercialization, and Progress of South Korean Joint Venture with The Stock Day Podcast



Phoenix, Arizona--(Newsfile Corp. - June 4, 2020) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO) ("the Company"), developer of sustainable technologies and a full-service environmental engineering company with a focus on clean water, clean air, and advanced antimicrobial products. President & CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly for an interview.
Jolly began by asking about the Company's subsidiary, Clyra Medical Technologies Inc., which recently launched a new product called Clyraguard. "This is a personal protection spray," explained Calvert. "It is hospital-grade, FDA-registered and cleared, and is 99.99% effective. This is an absolute winner," said Calvert.
"How big do you think this product can become?", asked Jolly. Calvert shared that Clyraguard has the potential to benefit a wide variety of people. "We know that it is the perfect product for a frontline healthcare worker," said Calvert, adding that the product is also suitable for individuals that are considered high-risk or are simply looking for protection against a number of pathogens. "We don't know of any product that matches the feature benefits of this product," said Calvert.
Calvert shared that Clyra has already begun selling the product, which is currently retailing at around $25 for a four-ounce bottle. "[Clyra is] building distribution as we speak, and adding team members to really help build that distribution. So, we think this is going to be a big blockbuster for the company."
Jolly then asked about the Company's patented CupriDyne® Clean product, and about the progress of their joint venture in South Korea. Calvert shared that the Company has finalized a joint venture with one of the leading waste water treatment groups in South Korea. "We got that transaction put together just a few months ago," said Calvert, discussing the tremendous potential of this agreement as the effects of the pandemic begin to subside.
"Where are we at with the PFAS solution?", asked Jolly, commenting on the Company's industrial water treatment technology aimed at eliminating per- and polyfluoroalkyl substances (PFAS) from water, called the BioLargo AEC. Calvert explained that the BioLargo AEC is a solution to the PFAS crisis which is both effective and affordable. "We'd like to be in commercial trials within the next 120 days," he continued, adding that the primary focus of this project is currently to produce a scaled-up version of the technology, which company management expects will be completed soon. Calvert explained that potential commercial trial clients are lining up.
To close the interview, Calvert expressed the potential of the Company's long list of technologies, which have continued to advance despite the current challenges of the pandemic. "We think that the future is right here before us," closed Calvert.
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Contact:
Name: Dennis P. Calvert
Phone: (888)-400-2863
Address: 14921 Chestnut St, Westminster CA, 92683
Email: dennis.calvert@biolargo.com
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Stock Day Media
(602) 821-1102

Wednesday, 3 June 2020

BioLargo CEO Dennis Calvert Sits Down for Interview with TMA BlueTech about "Uncommon Paths to CEO"




BioLargo President & CEO Dennis P. Calvert sat down for an interview with Katarina Jones of TMA BlueTech to discuss "Uncommon Paths to CEO". He offers commentary for young entrepreneurs interested in leadership in technology and innovation.

TMA BlueTech is a leading innovation cluster focused on promoting development and dissemination of science and technology that can protect our water and oceans. BioLargo is proud to be a member of this terrific organization.

Dennis Calvert has been an entrepreneur from age 4!  Some of his thoughts about the keys to running a successful business include:
- Teamwork is critical
- You can’t do it alone, no matter how hard you try
- Find every person’s special gift
- Have passion for what you’re working on

Thanks to interviewer Katarina Jones!  Visit her podcast "Otherwise Insights" to see more of Katarina's work.

Tuesday, 2 June 2020

Johnny Sirpilla Joins BioLargo’s Subsidiary Clyra Medical Technologies as Chief Business Development Officer

Westminster, CA – June 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that experienced business executive John A. Sirpilla has expanded his role from the Advisory Board of BioLargo’s partially owned subsidiary Clyra Medical Technologies, Inc., to serve as Clyra’s Chief Business Development Officer.

In his new role at the company, Mr. Sirpilla will work with Clyra’s senior executive team on brand expansion and retail channel development, and will work to develop strategic partnerships to help make Clyra products widely available to individuals, businesses, and the healthcare industry.

Mr. Sirpilla is the former President of Camping World Accessory Stores, a 140-store nationwide retail chain serving the RV industry and was promoted in 2012 to Chief Business Development Officer for the parent company, Camping World and Good Sam with annual sales of nearly $4 billion.   He is currently the CEO and founder of Encourage LLC (www.encourage33.com), a family office focused on driving change in healthy living, leadership, and child adoption. A long-time resident of Canton Ohio, Mr. Sirpilla also sits on the board of trustees of the Pro Football Hall of Fame, Hall of Fame Health, publicly traded LCI, Aultman Health Foundation, and other medical device boards.
Mr. Sirpilla joins the Clyra team as the company launches its FDA registered Clyraguard Personal Protection Spray to help protect personal protective equipment from the SARS-CoV-2 Coronavirus (COVID-19).

Mr. Sirpilla commented, “At Camping World, a portion of my responsibilities involved the oversight of call center operations, buying & merchandising, parts and accessories inventory, distribution center supply chain, store operations, and wholesale distribution. I believe strongly that these experiences will help me propel Clyra to the success it deserves. Clyra’s products fit well in my philosophy that inspiring others can lead to a positive impact on the world.”

Clyraguard is a spray designed to help prevent cross contamination by the SARS-CoV-2 Coronavirus, the cause of COVID-19 disease of the personal protective equipment worn by both front-line healthcare workers and consumers. Registered with the FDA as a Class I general purpose disinfectant, Clyraguard features an extremely high antimicrobial efficacy at 99.999% kill rate (complete inactivation), and the recent testing showed it inactivates the COVID-19 coronavirus below the limits of detection of the testing model.

More information about Clyraguard can be seen at the Clyra Medical website:  www.clyramedical.com/clyraguard


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies, Inc.
Clyra Medical Technologies (www.ClyraMedical.com) offers patented and patent pending effective, and safe, advanced antimicrobial products. Clyra has developed an FDA 510(k)-cleared product offering a Wound Irrigation Solution for advanced wound care available to hospitals and physicians in the U.S.

In addition, Clyra offers Clyraguard Personal Protective Spray, an effective, long-lasting disinfectant for personal protective equipment.

Clyra products are designed to offer the highest standards of antimicrobial and antiviral activity that are tissue and skin friendly, non-staining and are effective against biofilms.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Thursday, 28 May 2020

BioLargo Granted Expanded Patent Coverage for its AOS Water Treatment Technology


Westminster, CA – May 28, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced that it has been awarded a new US patent covering its innovative water treatment technology the Advanced Oxidation System (AOS), designed and manufactured by BioLargo’s subsidiary BioLargo Water, Inc. The AOS works by generating highly reactive iodine compounds which destroy water contaminants inside the AOS, while emitting safe, clean water. Compared to many competing technologies, the AOS costs less to install and operate, eliminates certain water contaminants existing systems cannot, and requires less electricity to treat water to enable safe water discharge and/or reuse.

The new patent – US 10,654,731 B2 – grants broader coverage (meaning it has fewer specific limitations) of the AOS and its components than previous patents covering the AOS, thereby providing greater intellectual property protection to the company as it works to begin commercial trials for the AOS technology and develops strategic commercial partnerships.

BioLargo Water President Dr. Richard Smith commented, “This patent was issued at a critical time, as we are hard at work establishing the first commercial trials for the AOS technology, after which we hope to achieve initial sales. With broad, secure intellectual property protection, we can launch this powerful and innovative technology without significant concern about competitors copying our designs. This is a great day for BioLargo and BioLargo Water, and we are proud of our team members who made this possible.”

BioLargo Water currently has a crowdfunding opportunity open. To learn more about this opportunity to invest in BioLargo Water, go to www.waterworksfund.com.


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About BioLargo Water
BioLargo Water, Inc. is an Alberta-based Canadian corporation headquartered at Agri-Food Discovery Place located on campus at the University of Alberta in Edmonton. BioLargo Water, Inc. developed and is commercializing the Advanced Oxidation System (AOS), a patented and proprietary technology aimed at providing cost- and energy-efficient treatment of water and wastewater to enable practical and affordable safe discharge and reuse of diverse water sources. Learn more at www.biolargowater.com. BioLargo Water, Inc. is a subsidiary of BioLargo Water Investment Group, Inc. (BWIG), which a subsidiary of BioLargo, Inc. (www.biolargo.com), an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  BioLargo features unique disruptive solutions to deliver clean air, clean water and a clean, safe environment.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Tuesday, 26 May 2020

Shawn Dougherty Joins BioLargo’s Subsidiary Clyra Medical Technologies as Chief Revenue Officer

Westminster, CA – May 26, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that its partially owned subsidiary Clyra Medical Technologies, Inc. has recruited Shawn Dougherty, experienced C-level executive responsible for several successful high-profile product launches, to serve as Clyra’s Chief Revenue Officer.

Shawn Dougherty is an entrepreneur with substantial experience growing sales and revenues for new and innovative products. Prior to joining Clyra, Shawn co-founded mophie, the number one selling battery case manufacturer for mobile devices in North America. As COO and founder, she helped mophie create the first juice pack battery case for the iPhone in North America and built an exclusive partnership with Apple. With time, they created a solid business structure, allowing the company to thrive and withstand rapid growth, both in the U.S. and internationally. mophie raised millions of dollars in multiple rounds of capital and debt facilities. Under Shawn's guidance and strategic vision, the company grew from three employees in a barn in Michigan to a multi-million-dollar business with 300+ employees in five facilities in California, Michigan, China, Hong Kong and Amsterdam.

Shawn joins the Clyra team as the company has just launched its FDA registered Clyraguard personal protection spray to help protect non-critical personal protective equipment from the SARS-CoV-2 Coronavirus (COVID-19).

Clyraguard is a spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 Coronavirus, the cause of COVID-19 disease. Registered with the FDA as a Class I general purpose disinfectant, Clyraguard features an extremely high antimicrobial efficacy at 99.999% kill rate (complete inactivation), and the recent testing showed it inactivates the COVID-19 coronavirus below the limits of detection of the testing model.

More information about Clyraguard can be seen at the Clyra Medical website:  www.clyramedical.com/clyraguard 


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies, Inc.
Clyra Medical Technologies (www.ClyraMedical.com) offers patented and patent pending effective, and safe, advanced antimicrobial products. Clyra has developed an FDA 510(k)-cleared product offering a Wound Irrigation Solution for advanced wound care available to hospitals and physicians in the U.S.

In addition, Clyra offers Clyraguard Personal Protective Spray, an effective, long-lasting disinfectant for personal protective equipment.

Clyra products are designed to offer the highest standards of antimicrobial and antiviral activity that are tissue and skin friendly, non-staining and are effective against biofilms.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Friday, 22 May 2020

Proactive Investors Interview May 22: BioLargo CEO Discusses Clyraguard




BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive that Clyraguard, a spray developed by its subsidiary Clyra Medical Technologies, was shown to cause complete inactivation of the coronavirus in lab testing.

Calvert says Clyraguard is a personal protective spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment from the coronavirus.

Thursday, 21 May 2020

BioLargo’s CupriDyne Technology Proven Effective at Inactivating SARS-CoV-2

Source: Accesswire (https://www.accesswire.com/590846/BioLargos-CupriDyne-Technology-Proven-Effective-at-Inactivating-SARS-CoV-2)


Westminster, CA – May 21, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that its patented CupriDyne® technology has been proven in a third-party study to be effective in inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. The study was conducted by researchers at the Galveston National Laboratory (GNL), a biosafety level (BSL) level 3 lab associated with the University of Texas Medical Branch (UTMB).


To introduce a product to market that can make a COVID-19 claim, BioLargo will need approval from the Environmental Protection Agency. It has retained an EPA consultant and is considering the options to fast-track an application, including through a special Section 18 exemption. Management believes that a CupriDyne based COVID-19 product would provide a safe, environmentally friendly spray or misting product to enable effective decontamination of enclosed spaces and public places, and would provide an additional tool for protection to front-line workers and vulnerable persons as governments begin to allow businesses to reopen.

Results of the study conducted by the Galveston National Lab have been published here: https://www.biorxiv.org/content/10.1101/2020.05.08.082701v1

The study concluded:
“The novel iodine complex tested herein offers a safe and gentle alternative
to conventional disinfectants for use on indoor and outdoor surfaces.”

Dennis P. Calvert, President & CEO of BioLargo commented, “Iodine has a long history of use as a first-line disinfectant and antiviral agent, so it does not come as a surprise that CupriDyne was found to be effective against SARS-CoV-2. Research also shows that iodine-containing solutions were used in previous pandemics, including the 1918 Spanish Flu, and the SARS and MERS outbreaks in 2006 and 2013. Our products offer a unique, non-toxic and non-staining form of iodine that is exceptionally suited to help stop spread of this virus.”

About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Galveston National Laboratory/UTMB
The Galveston National Laboratory (GNL) is a sophisticated high containment research facility that serves as a critically important resource in the global fight against infectious diseases. The GNL is located on the campus of the University of Texas Medical Branch and operates under the umbrella of UTMB’s Institute for Human Infections and Immunity.

The National Institute of Allergy and Infectious Diseases (NIAID) provides funding for the BSL4 laboratories and operations at the GNL, and the lab’s top priority is research to develop diagnostics, therapeutics and vaccines to combat the most dangerous diseases in the world.

Researchers at the GNL are internationally known for their expertise working with pathogens including Ebola and Marburg, emerging infectious diseases like MERS, and mosquito borne viruses like Zika and Chikungunya. The Galveston National Laboratory is home to research that is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the Biopharmaceutical industry.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Wednesday, 20 May 2020

Protecting People from Viruses in Water


Now and in the future, detecting and eliminating bacteria and viruses in water and wastewater may be more important than ever. Broadly, we anticipate global health pandemics will increase the need for new and existing advanced water disinfection technologies.

We’re BioLargo Water and eliminating pathogens and pollution from water is what we do.  

That’s why we’re asking you to consider joining with us by investing in BioLargo Water and our effective, affordable new treatment technology for water disinfection, the Advanced Oxidation System – AOS.

Water and wastewater can be a transmission route for bacteria and viruses.  Our AOS technology offers an effective, affordable, energy-efficient virus disinfection tool for water utilities and private businesses.  In addition, our AOS technology has been proven effective against viruses (as tested with standard virus surrogates), and we intend to help fill new market gaps for highly effective, cost-efficient solutions as they emerge.

Why consider joining us and investing in BioLargo Water and our AOS:

Our system costs less and does more.
Compared to many competing technologies, AOS: (1) costs less to install and operate; (2) allows on-site water recycling and reuse, or safe discharge; (3) eliminates contaminants and pollutants existing systems can’t; (4) hits multiple different contaminant classes with one system, rather than requiring multiple technologies; and, (5) requires less space.

We’re not starting at ground zero.
Since 2015, almost $4 million has been invested on research and development to create the BioLargo Water AOS. Funding has been primarily through industry and government partnerships.

It’s working.
Modular, compact and cost-effective, AOS succeeds where many existing technologies can't. In 2019, at a poultry processing facility pilot project, AOS-treated water met all local water re-use and discharge standards and adhered to standards of the United States Department of Agriculture (USDA) and Environmental Protection Agency (EPA).

Smart people. Powerful backing.
The BioLargo Water team of Ph.D. scientists and engineers has created a breakthrough product. Now — with the technical support, marketing and finance resources, and more, of our parent company BioLargo, Inc. — AOS stands poised to enter the wastewater market.


BioLargo Water, Inc., is led by an experienced management team with diverse talents and specialties. These exceptionally qualified PhDs and engineers are recognized as industry experts, with 20+ years of executive experience on average.

Please visit the below link and consider joining us by investing in BioLargo Water and together let’s help protect water, and us, from future viruses.


Thank you,
BioLargo Water Team